Natera announced the publication of a peer‑reviewed validation study of its Latitude tissue‑free molecular residual disease (tfMRD) assay in colorectal cancer. The study, appearing in npj Precision Oncology, evaluated 1,230 time‑points from 195 patients enrolled in the GALAXY clinical trial and confirmed the assay’s analytical performance and clinical relevance for detecting residual disease after treatment.
The Latitude tfMRD test builds on Natera’s tumor‑informed cfDNA platform and is methylation‑based. It uses multiplex PCR amplification followed by next‑generation sequencing to identify clonal mutations specific to each patient’s tumor. The assay demonstrated a longitudinal sensitivity of 84.4 %, a median lead time of 4.6 months ahead of radiographic recurrence, a sample‑level specificity of 97.2 % and a patient‑level specificity of 92.1 %.
Clinically, MRD‑positivity was strongly associated with worse outcomes: a hazard ratio of 10.0 (p < 0.001) in the MRD setting and 31.9 (p < 0.001) in the surveillance setting. The study also showed that high‑risk stage II and III patients who were MRD‑positive derived a measurable benefit from adjuvant chemotherapy, underscoring the test’s predictive value.
The validation supports Natera’s upcoming submission to the Centers for Medicare & Medicaid Services’ Molecular Diagnostics Services Program (MolDX) and is expected to accelerate payer coverage decisions. By providing a tissue‑free alternative to the tumor‑informed Signatera test, Latitude expands Natera’s cfDNA portfolio and positions the company to capture new revenue streams in oncology, women's health, and organ health.
Natera’s strong financial performance in the preceding quarter—39 % year‑over‑year revenue growth and 35 % growth for the full year—has already bolstered investor confidence. Analysts have raised price targets and expressed a “moderate buy” stance, citing the company’s robust Signatera franchise and the momentum from the Latitude validation. The market reaction has been driven by the combination of solid earnings, the clinical validation of a new product, and the strategic implications for reimbursement and adoption.
Dr. Minetta Liu, Natera’s chief medical officer of oncology and early cancer detection, said, “Latitude delivers high‑performance MRD detection for clinical situations where tumor‑informed testing with Signatera is not possible or practical.” She added that the test has generated strong interest since its 2025 launch and that Natera plans to offer it in additional histologies.
In the competitive landscape, Natera faces rivals such as Guardant Health, Exact Sciences, and Foundation Medicine. Latitude’s tissue‑free design gives it a distinct advantage when tumor tissue is unavailable, complementing the Signatera test and strengthening Natera’s position in the rapidly growing MRD market.
The publication marks a significant milestone for Natera, setting the stage for regulatory and payer approvals that could unlock new revenue streams and reinforce the company’s growth strategy across multiple therapeutic areas.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.